Advanced BioScience Labs

Executive Summary

Advanced BioScience Labs (ABL) is a U.S.-based CDMO and CRO with over 50 years of experience in advanced biotherapeutics, including gene therapies, vaccines, oncolytic viruses, and immunotherapies. Headquartered in Rockville, Maryland, ABL offers integrated services from discovery through commercial manufacturing, leveraging expertise in viral vector biomanufacturing, immunobiology, and GMP operations. Despite being privately held and classified as pre-clinical in stage, ABL primarily supports client programs targeting infectious diseases and other challenging conditions. The company’s long-standing presence and specialized capabilities position it as a reliable partner in the growing cell and gene therapy market, though its own pipeline remains undisclosed.

Upcoming Catalysts (preview)

• Q3 2026Expansion of GMP manufacturing capacity for viral vectors70% success
• Q4 2026Strategic partnership with a top-20 pharma company for gene therapy development50% success
• Q1 2027Launch of next-generation lentiviral vector platform60% success